Large-scale epidemiological monitoring of the COVID-19 epidemic in Tokyo.


Journal

The Lancet regional health. Western Pacific
ISSN: 2666-6065
Titre abrégé: Lancet Reg Health West Pac
Pays: England
ID NLM: 101774968

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 29 04 2020
revised: 05 08 2020
accepted: 19 08 2020
entrez: 26 6 2021
pubmed: 27 6 2021
medline: 27 6 2021
Statut: ppublish

Résumé

On April 7, 2020, the Japanese government declared a state of emergency regarding the novel coronavirus (COVID-19). Given the nation-wide spread of the coronavirus in major Japanese cities and the rapid increase in the number of cases with untraceable infection routes, large-scale monitoring for capturing the current epidemiological situation of COVID-19 in Japan is urgently required. A chatbot-based healthcare system named COOPERA (COvid-19: Operation for Personalized Empowerment to Render smart prevention And AN care seeking) was developed to surveil the Japanese epidemiological situation in real-time. COOPERA asked questions regarding personal information, location, preventive actions, COVID-19 related symptoms and their residence. Empirical Bayes estimates of the age-sex-standardized incidence rate and disease mapping approach using scan statistics were utilized to identify the geographical distribution of the symptoms in Tokyo and their spatial correlation We analyzed 353,010 participants from Tokyo recruited from 27th March to 6th April 2020. The mean (SD) age of participants was 42.7 (12.3), and 63.4%, 36.4% or 0.2% were female, male, or others, respectively. 95.6% of participants had no subjective symptoms. We identified several geographical clusters with high spatial correlation ( With the global spread of COVID-19, medical resources are being depleted. A new system to monitor the epidemiological situation, COOPERA, can provide insights to assist political decision to tackle the epidemic. In addition, given that Japan has not had a strong lockdown policy to weaken the spread of the infection, our result would be useful for preparing for the second wave in other countries during the next flu season without a strong lockdown. The present work was supported in part by a grant from the Ministry of Health, Labour and Welfare of Japan (H29-Gantaisaku-ippan-009).

Sections du résumé

BACKGROUND BACKGROUND
On April 7, 2020, the Japanese government declared a state of emergency regarding the novel coronavirus (COVID-19). Given the nation-wide spread of the coronavirus in major Japanese cities and the rapid increase in the number of cases with untraceable infection routes, large-scale monitoring for capturing the current epidemiological situation of COVID-19 in Japan is urgently required.
METHODS METHODS
A chatbot-based healthcare system named COOPERA (COvid-19: Operation for Personalized Empowerment to Render smart prevention And AN care seeking) was developed to surveil the Japanese epidemiological situation in real-time. COOPERA asked questions regarding personal information, location, preventive actions, COVID-19 related symptoms and their residence. Empirical Bayes estimates of the age-sex-standardized incidence rate and disease mapping approach using scan statistics were utilized to identify the geographical distribution of the symptoms in Tokyo and their spatial correlation
FINDINGS RESULTS
We analyzed 353,010 participants from Tokyo recruited from 27th March to 6th April 2020. The mean (SD) age of participants was 42.7 (12.3), and 63.4%, 36.4% or 0.2% were female, male, or others, respectively. 95.6% of participants had no subjective symptoms. We identified several geographical clusters with high spatial correlation (
INTERPRETATION CONCLUSIONS
With the global spread of COVID-19, medical resources are being depleted. A new system to monitor the epidemiological situation, COOPERA, can provide insights to assist political decision to tackle the epidemic. In addition, given that Japan has not had a strong lockdown policy to weaken the spread of the infection, our result would be useful for preparing for the second wave in other countries during the next flu season without a strong lockdown.
FUNDING BACKGROUND
The present work was supported in part by a grant from the Ministry of Health, Labour and Welfare of Japan (H29-Gantaisaku-ippan-009).

Identifiants

pubmed: 34173599
doi: 10.1016/j.lanwpc.2020.100016
pii: S2666-6065(20)30016-X
pmc: PMC7546969
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100016

Informations de copyright

© 2020 The Authors. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Dr. Miyata reports grants from Ministry of Health, Labour and Welfare of Japan, during the conduct of the study.

Références

JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
J Epidemiol. 2020 Aug 5;30(8):362-370
pubmed: 32475884
Biometrics. 1987 Sep;43(3):671-81
pubmed: 3663823
Geospat Health. 2019 Nov 06;14(2):
pubmed: 31724375
Stat Med. 1995 Apr 30;14(8):799-810
pubmed: 7644860
Lancet. 2016 Sep 3;388(10048):942-3
pubmed: 27402382
Acta Trop. 2018 Sep;185:77-85
pubmed: 29709630
J R Stat Soc Ser C Appl Stat. 1991;40(2):283-94
pubmed: 12157989
Appl Geogr. 2020 May;118:102202
pubmed: 32287518
Stat Med. 1985 Apr-Jun;4(2):201-12
pubmed: 4023478
PLoS Negl Trop Dis. 2019 Sep 23;13(9):e0007266
pubmed: 31545819
N Engl J Med. 2003 Dec 18;349(25):2431-41
pubmed: 14681510

Auteurs

Daisuke Yoneoka (D)

Department of Health Policy and Management, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
Graduate School of Public Health, St. Luke's International University, Tokyo, Japan.
Department of Global Health Policy, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Yuta Tanoue (Y)

Institute for Business and Finance, Waseda University, Tokyo, Japan.

Takayuki Kawashima (T)

Department of Mathematical and Computing Science, Tokyo Institute of Technology, Tokyo, Japan.

Shuhei Nomura (S)

Department of Health Policy and Management, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
Department of Global Health Policy, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Shoi Shi (S)

Department of Systems Pharmacology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Laboratory for Synthetic Biology, RIKEN Center for Biosystems Dynamics Research, Osaka, Japan.

Akifumi Eguchi (A)

Center for Preventive Medical Sciences, Chiba University, Chiba, Japan.

Keisuke Ejima (K)

Department of Epidemiology and Biostatistics, Indiana University School of Public Health-Bloomington, Bloomington, USA.

Toshibumi Taniguchi (T)

Department of Infectious Diseases, Chiba University, Chiba, Japan.

Haruka Sakamoto (H)

Department of Health Policy and Management, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
Department of Global Health Policy, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Hiroyuki Kunishima (H)

Department of Infectious Diseases, School of Medicine, St. Marianna University, Kanagawa, Japan.

Stuart Gilmour (S)

Graduate School of Public Health, St. Luke's International University, Tokyo, Japan.

Hiroshi Nishiura (H)

Graduate School of Medicine, Hokkaido University, Hokkaido, Japan.

Hiroaki Miyata (H)

Department of Health Policy and Management, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.

Classifications MeSH